Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Start Date
2/26/2024
Completion Date
12/1/2028
Summary
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
Detailed Description
This is a prospective, multicenter, nonrandomized single-arm study assessing the diagnostic accuracy of PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) in determining the absence of clinically significant prostate cancer in patients on active surveillance (AS).The trial will enroll 200 subjects for low and favorable intermediate-risk prostate cancer patients per NCCN guidelines who have elected to pursue active surveillance.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
PSMA-PET CT
Conditions
Locations
UCLA
Los Angeles, California 90005
United States
UCSF
San Francisco, California 94143
United States
Weill Cornell Medicine - New York Presbyterian Hospital
New York, New York 10065
United States
UH Cleveland Medical Center
Cleveland, Ohio 44106
United States